Answers are grounded in this paper and cite their sources.
T he need for a continuous supply of safe and readily available platelets (PLTs) continues to be a challenge within the transfusion community, with variability in donation rates affecting inventory and the limited shelf life contributing to wastage. Innovative technologies such as pathogen inactivation have significantly increased the safety of PLTs, however, the shelf life problem remains. Cold storage of PLT units should reduce bacterial contamination, but it remains to be seen whether these PLTs will retain their efficacy after extended storage. Cryopreserved PLTs, which carry a minimal bacterial contamination risk and can be stored for several years, represent a potential solution worth exploring. The first attempt at frozen PLT storage was made in 1956, when PLT pellets were stored at −15 C in a minimal volume of plasma (15-30 mL) with no cryoprotectant added. After 6 weeks, the PLTs were thawed and transfused into pediatric patients with thrombocytopenia. Despite moderate success—with nearly two-thirds of transfusions yielding transitory hemostasis and no reported thrombotic events— additional work with frozen PLTs was limited until 1974, when Valeri and colleagues published their 6% dimethyl sulfoxide (DMSO) method. This protocol cryopreserves PLT concentrates at −80 C followed by a postthaw wash to remove the DMSO. In 2005 Valeri and coworkers published an improved “no-wash” method in which the DMSO was removed prior to freezing the pelleted PLTs, thus eliminating the postthaw washing steps and reducing the volume of frozen units. The no-wash method, with 5% to 6% DMSO, is currently the most popular process used to manufacture cryopreserved PLTs. Platelets are prone to activation from handling, so it is not surprising that a cycle of freezing and thawing affects their function. in vitro characterization of cryopreserved PLTs has uncovered changes inmorphology and surfacemarker expression that are consistent with a partially activated phenotype. When compared to conventional room temperature liquid-stored PLTs, cryopreserved PLTs show a loss of discoid shape, elevated levels of P-selectin, increased exposure of phosphatidylserine on the outer membrane, and an elevated level of phenotypically distinct microparticles. This phenotype leads to the obvious question: Could this preactivated state tilt cryopreserved PLTs toward hypercoagulation in vivo? Additional in vitro tests reveal nuances that may reflect a more balanced hemostatic potential in vivo. In the thrombin generation assay, cryopreserved PLTs generate a greater thrombin peak height with a shortened reaction lag time compared to liquid-stored PLTs. However, the endogenous thrombin potential of cryopreserved PLTs is only slightly higher than liquid-stored PLTs, which suggests that the clotting effects of cryopreserved PLTs and liquid-stored PLTs are similar. Tests with thromboelastography (TEG) and rotational thromboelastometry (ROTEM) showed faster clot initiation with cryopreserved PLTs than conventional PLTs. However, the clot firmness with cryopreserved PLTs was approximately half that of liquidstored PLTs. Finally, elegant tests with microfluidic chambers showed that compared to conventional PLTs, adhesion of cryopreserved PLTs to collagen was reduced, but fibrin deposition was similar. While in vitro tests offer important insights into functional pathways, it is the in vivo function, efficacy, and safety of cryopreserved PLTs that are critical. Valeri and colleagues showed that cryopreserved PLTs were functionally competent by transfusing cryopreserved PLTs into healthy subjects given aspirin to inhibit their native PLT function. They found that a single unit of cryopreserved PLTs shortened the aspirin-induced prolonged bleeding time, consistent with cryopreserved PLTs maintaining their basic function. While these controlled experiments were being run, Schiffer and colleagues began transfusing cryopreserved PLTs into highly alloimmunized thrombocytopenic patients after chemotherapy. From 1974 to 1981, approximately 1,600 cryopreserved PLT units (>700 autologous units) were transfused into 155 patients with no serious adverse events reported. They found that cryopreserved PLT transfusions reduced bleeding times more effectively than liquid-stored PLTs. However, posttransfusion increments in PLT count were approximately 60% of those seen with liquid-stored PLTs. Importantly, since HLA-matched units were not readily available in the 1970s, autologous cryopreserved PLTs were the only source of HLA-compatible units for many of these patients. Applying this concept, a Swiss group used autologous cryopreserved PLTs for thrombocytopenic alloimmunized/ refractory patients undergoing chemotherapy. To manufacture cryopreserved PLTs they used 10% DMSO and did not remove the DMSO. After transfusing 40 autologous cryopreserved PLTs units, they reported a significantly higher median 1-hour PLT count increment compared to liquid-stored, ABO-matched but HLA-unselected PLT units. No major bleeds or serious adverse events were observed. The Dutch military was another important group to recognize the advantages of cryopreserved PLTs. Realizing that extended storage would be useful in the logistically challenging and austere environment of forward combat zones, the Dutch began producing cryopreserved PLTs in 2001 to treat casualties incurred during deployment. They doi:10.1111/trf.15465 © 2019 AABB TRANSFUSION 2019;59;2759–2762
No takes yet. Share an insight, caveat, or question.
Cohn et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: